PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

98 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
61.
Lang, D.M. ; Peeken, J.C. ; Combs, S.E. ; Wilkens, J.J.* & Bartzsch, S.: Deep learning based HPV status prediction for oropharyngeal cancer patients. Cancers 13:786 (2021)
62.
Li, W.B. et al.: Application of high‐Z gold nanoparticles in targeted cancer radiotherapy—pharmacokinetic modeling, Monte Carlo simulation and radiobiological effect modeling. Cancers 13:5370 (2021)
63.
Madhavan, B.K.* et al.: Elevated expression of the rage variant-v in sclc mitigates the effect of chemotherapeutic drugs. Cancers 13:2843 (2021)
64.
Mancini, M.* ; Righetto, M.* & Nößner, E.: Checkpoint inhibition in bladder cancer: Clinical expectations, current evidence, and proposal of future strategies based on a tumor-specific immunobiological approach. Cancers 13:6016 (2021)
65.
Merkle, J.* et al.: Cdkn2a-mutated pancreatic ductal organoids from induced pluripotent stem cells to model a cancer predisposition syndrome. Cancers 13:5139 (2021)
66.
Mohr, H. et al.: Mutation of the cell cycle regulator p27kip1 drives pseudohypoxic pheochromocytoma development. Cancers 13:126 (2021)
67.
Patzelt, L.* et al.: Mri‐determined psoas muscle fat infiltration correlates with severity of weight loss during cancer cachexia. Cancers 13:4433 (2021)
68.
Peeken, J.C. et al.: Prognostic assessment in high-grade soft-tissue sarcoma patients: A comparison of semantic image analysis and radiomics. Cancers 13:1929 (2021)
69.
Romano, M.* et al.: A multi-scale and multi-technique approach for the characterization of the effects of spatially fractionated X-ray radiation therapies in a preclinical model. Cancers 13:4953 (2021)
70.
Schwab, M.* et al.: Targeting cancer metabolism breaks radioresistance by impairing the stress response. Cancers 13:3762 (2021)
71.
Sharaf, K.* et al.: Human adipose-derived stem/stromal cells promote proliferation and migration in head and neck cancer cells. Cancers 13:2751 (2021)
72.
Spella, M.* & Stathopoulos, G.T.: Immune resistance in lung adenocarcinoma. Cancers 13:384 (2021)
73.
Steel, H.* ; Brüningk, S.C.* ; Box, C.* ; Oelfke, U.* & Bartzsch, S.: Quantification of differential response of tumour and normal cells to microbeam radiation in the absence of flash effects. Cancers 13:3238 (2021)
74.
Wagner, A.E.* et al.: Erratum: Wagner, A.E., et al. SP8 promotes an aggressive phenotype in hepatoblastoma via FGF8 activation. (Cancers 2020, 12, 2294). Cancers 13:362 (2021)
75.
Weusthof, K.* et al.: Neurocognitive outcomes in pediatric patients following brain irradiation. Cancers 13:3538 (2021)
76.
Anastasov, N. et al.: Mek1 inhibitor combined with irradiation reduces migration of breast cancer cells including mir-221 and zeb1 emt marker expression. Cancers 12:3760 (2020)
77.
Frankó, A. et al.: Human prostate cancer is characterized by an increase in urea cycle metabolites. Cancers 12:1814 (2020)
78.
Gambichler, T.* et al.: Cancer and immune checkpoint inhibitor treatment in the era of SARS-CoV-2 infection. Cancers 12:3383 (2020)
79.
Kafka, M.* et al.: Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer. Cancers 12:2092 (2020)
80.
Kirstein, A. ; Schmid, T.E. & Combs, S.E.: The role of miRNA for the treatment of MGMT unmethylated glioblastoma multiforme. Cancers 12:1099 (2020)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... ▶▶ ▶▮